Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enveric Biosciences Inc (ENVB)

Enveric Biosciences Inc (ENVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,334
  • Shares Outstanding, K 597
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,570 K
  • EBIT $ -10 M
  • EBITDA $ -9 M
  • 60-Month Beta 0.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.56

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.60 +0.83%
on 12/31/25
13.25 -72.60%
on 12/10/25
-2.11 (-36.76%)
since 11/28/25
3-Month
3.60 +0.83%
on 12/31/25
13.25 -72.60%
on 12/10/25
-4.04 (-52.69%)
since 09/30/25
52-Week
3.60 +0.83%
on 12/31/25
96.30 -96.23%
on 01/07/25
-55.12 (-93.82%)
since 12/30/24

Most Recent Stories

More News
Enveric Biosciences Announces Patent Issuance

U.S. Patent expands the scope of patent protection and increases the number of molecules that Enveric has the potential to develop or license for the treatment of neuropsychiatric conditions.

ENVB : 3.63 (-7.16%)
ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of...

ENVB : 3.63 (-7.16%)
FEED : 2.31 (+5.96%)
Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological...

ENVB : 3.63 (-7.16%)
Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological...

ENVB : 3.63 (-7.16%)
Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Once issued, this new U.S. Patent will expand the scope of Enveric’s EVM301 patent portfolio of potential neuroplastogenic molecules for treatment of neuropsychiatric conditions.

ENVB : 3.63 (-7.16%)
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Management to meet with investors and potential partners during Biotech Showcase 2026

ENVB : 3.63 (-7.16%)
Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Once issued, this new U.S. Patent will expand the scope of Enveric’s EVM401 patent portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions.

ENVB : 3.63 (-7.16%)
Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional positive data in a preclinical model of PTSD, successful completion...

ENVB : 3.63 (-7.16%)
Enveric Biosciences Announces Reverse Stock Split

Common Stock Will Begin Trading on a Split-Adjusted Basis on October 28, 2025

ENVB : 3.63 (-7.16%)
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

New patent marks Enveric’s 23 rd issued U.S. patent for novel neuroplastogen molecules, increasing Enveric’s intellectual property footprint and supporting the potential for pipeline...

ENVB : 3.63 (-7.16%)

Business Summary

Enveric Biosciences Inc. is a patient-centric biotechnology company endeavoring to enhance the lives of Cancer Treatments with novel cannabinoid medicines. Enveric Biosciences Inc., formerly known as AMERI Holdings Inc., is based in NAPLES, Fla.

See More

Key Turning Points

3rd Resistance Point 4.15
2nd Resistance Point 4.04
1st Resistance Point 3.83
Last Price 3.63
1st Support Level 3.51
2nd Support Level 3.40
3rd Support Level 3.19

See More

52-Week High 96.30
Fibonacci 61.8% 60.89
Fibonacci 50% 49.95
Fibonacci 38.2% 39.01
Last Price 3.63
52-Week Low 3.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar